Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunothera
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
